Xencor (XNCR) shares increased by 16.9% on the last trading day, closing at $17.47, driven by significant trading volume. Over the past four weeks, the stock has risen a total of 18.3%. The surge in investor confidence is attributed to progress in Xencor’s pipeline, particularly in oncology, with its lead candidate XmAb819 showing promise for advanced clear cell renal cell carcinoma (ccRCC), set for a presentation at the ESMO Congress 2026, and a pivotal study planned for 2027.
For its upcoming quarterly report, Xencor is expected to post a loss of $0.84 per share, marking a year-over-year decline of 104.9%. Projected revenues are anticipated to be $9.97 million, a decrease of 77.1% from the previous year. Meanwhile, the company’s consensus earnings estimate has remained unchanged over the last 30 days, and it is currently rated as a Zacks Rank #3 (Hold).
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
